Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients - Top-Institutions - MDSpire

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

  • By

  • Song Cheng

  • Dabin Chen

  • Rongrong Du

  • Chao Wang

  • Jiawen Xian

  • Liyuan Liu

  • Hong Wan

  • Ting Ye

  • May 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Affiliated Hospital of Southwest Medical University
    Affiliated Hospital of Southwest Medical University

    Nanchong, Sichuan

    Key Differentiators

    • Oncology

  • #2

    GARNET trial
    GARNET trial

    N/A, N/A

    Key Differentiators

    • Oncology

  • #3

    10 institutions in the United States and Europe
    10 institutions in the United States and Europe

    N/A, N/A

    Key Differentiators

    • Oncology

  • #4

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #5

    North Estonia Medical Centre (NEMC) Foundation
    North Estonia Medical Centre (NEMC) Foundation

    Tallinn, Harju

    Key Differentiators

    • Oncology

Original Source(s)

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

  • by Song Cheng, Dabin Chen, Rongrong Du, Chao Wang, Jiawen Xian, Liyuan Liu, Hong Wan, Ting Ye

  • May 26, 2026

Related Content

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy